These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1279334)

  • 61. The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.
    Yeo B; Redfern AD; Mouchemore KA; Hamilton JA; Anderson RL
    Clin Exp Metastasis; 2018 Apr; 35(4):255-267. PubMed ID: 29968171
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Idiopathic myxedema * atrophic thyroiditis].
    Nomura E; Toyoda N; Nishikawa M
    Nihon Rinsho; 2006 May; Suppl 1():333-6. PubMed ID: 16776158
    [No Abstract]   [Full Text] [Related]  

  • 63. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project.
    Tigue CC; McKoy JM; Evens AM; Trifilio SM; Tallman MS; Bennett CL
    Bone Marrow Transplant; 2007 Aug; 40(3):185-92. PubMed ID: 17563736
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Predisposition to thyroid autoimmune diseases].
    Makni H; Makni-Krichene S; Abid M; Jouida J; Jarraya A; Charreire J; Ayadi H
    Presse Med; 1997 Sep; 26(25):1181-5. PubMed ID: 9380608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Immunologic and cytologic aspects of Hashimoto's thyroiditis during therapy with thymopentin].
    Aiello A; Cristofaro M; Carrozza F; Di Rienzo G; Carile L
    Clin Ter; 1990 May; 133(4):227-31. PubMed ID: 2142910
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Changes in markers of autoimmunity in patients with Hashimoto thyroiditis treated with intravenous immunoglobulins. Preliminary results].
    Antonelli A; Alberti B; Melosi A; Saracino A; Agostini S; Gambuzza C; Neri S; Baschieri L
    Clin Ter; 1992 Sep; 141(9 Pt 2):37-42. PubMed ID: 1468196
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical toxicity of cytokines used as haemopoietic growth factors.
    Vial T; Descotes J
    Drug Saf; 1995 Dec; 13(6):371-406. PubMed ID: 8652081
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
    Frampton JE; Yarker YE; Goa KL
    Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reversible thyroid dysfunction with filgrastim.
    de Luis DA; Romero E
    Lancet; 1996 Dec; 348(9041):1595-6. PubMed ID: 8950916
    [No Abstract]   [Full Text] [Related]  

  • 70. Long-term lithium treatment and thyroid antibodies: a controlled study.
    Baethge C; Blumentritt H; Berghöfer A; Bschor T; Glenn T; Adli M; Schlattmann P; Bauer M; Finke R
    J Psychiatry Neurosci; 2005 Nov; 30(6):423-7. PubMed ID: 16327876
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Cytokine therapy and the endocrine system: is it necessary to monitor more than the thyroid gland?].
    Schuppert F; Müller-Kunert E; Stöcker W; Bokemeyer C; Schmoll HJ; von zur Mühlen A; Rambusch EG
    Med Klin (Munich); 1996 Feb; 91(2):59-65. PubMed ID: 8850099
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk of thyroid dysfunction during treatment with G-CSF.
    Van Hoef ME; Howell A
    Lancet; 1992 Nov; 340(8828):1169-70. PubMed ID: 1279334
    [No Abstract]   [Full Text] [Related]  

  • 73. AUTOIMMUNE DISEASE AND THYROID AUTOANTIBODIES.
    BOONSHAFT B
    Mo Med; 1964 Mar; 61():182-9. PubMed ID: 14125332
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.